Skin News and Research

RSS

Womb cancer is the fourth most common cancer among UK women: Research

Womb cancer cases are highest ever for over three decades.The number of women diagnosed with womb cancer is at its highest for over 30 years according to new figures published today by Cancer Research UK which show more than 7,530 people now develop the disease each year in the UK.

22 Jul 2010

NovaBay reports positive results from NVC-422 Phase 2a proof-of-concept clinical trial for impetigo

NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.

21 Jul 2010

Wellstar announces Delivery of 2 Prototypes of the TMI Clinical Camera Design

Wellstar through its wholly owned subsidiary Trillennium Medical Imaging (TMI) announces the Delivery of 2 Prototypes of the TMI Clinical Camera Design.

21 Jul 2010

Scientists identify key genes for Silk Road disease

Scientists have identified key genes responsible for a severe inflammatory disease that has spread along the old silk trading routes from the Far East to the edge of Europe.University of Manchester researchers, working as part of a large international consortium, have revealed some of the genetic mutations that lead to Behçet's disease. The group's findings are published in Nature Genetics.

21 Jul 2010

Arcion reports top-line results from ARC-4558 Phase 2b clinical trial for painful diabetic neuropathy

Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced top-line results from a successful Phase 2b double-blind, randomized, placebo-controlled clinical trial of its lead topical pain candidate, ARC-4558, in adult patients with painful diabetic neuropathy (PDN). Arcion recently held an End of Phase 2 meeting with the United States Food and Drug Administration (FDA) and the ARC-4558 program is now poised to enter Phase 3 studies.

20 Jul 2010

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson today announced sales of $15.3 billion for the second quarter of 2010, an increase of 0.6% as compared to the second quarter of 2009. Operational results increased 0.1% and the positive impact of currency was 0.5%. Domestic sales declined 2.8%, while international sales increased 4.1%, reflecting operational growth of 3.0% and a positive currency impact of 1.1%.

20 Jul 2010

Diffused ultraviolet radiation penetrates beach umbrellas

A team of researchers from the University of Valencia (UV) has proven that 34% of ultraviolet radiation filters through under beach umbrellas. According to what is published in the journal Photochemistry and Photobiology, umbrellas intercept the full direct flow that comes from the Sun, but not the diffused radiation that penetrates through from the sides.

20 Jul 2010

Ivy nanoparticles protect skin from UV radiation better than metal-based sunblocks: Study

When Mingjun Zhang was watching his son play in the yard, he was hit with a burning question: "What makes the ivy in his backyard cling to the fence so tightly?" That simple question has led to a pioneering discovery that the tiny particles secreted from ivy rootlets can be used in many breakthrough applications in items such as military technologies, medical adhesives and drug delivery, and, most recently, sun-block.

20 Jul 2010

Researchers reveal findings on restricted lineage of iPS cells

Adult cells that have been reprogrammed into induced pluripotent stem cells (iPS cells) do not completely let go of their past, perhaps limiting their ability to function as a less controversial alternative to embryonic stem cells for basic research and cell replacement therapies, according to researchers at Children's Hospital Boston, John Hopkins University and their colleagues

20 Jul 2010

Rice University bioengineers win $1.7M NIH grant for cartilage-regeneration research

Bioengineers from Rice University's BioScience Research Collaborative have won a $1.7 million grant from the National Institutes of Health to develop an injectable mix of polymers and adult stem cells that can spur the growth of new cartilage in injured knees and other joints.

20 Jul 2010

T-SPOT.TB test predicts TB infected persons better than TST: Study

The authors of a recent study published in the American Journal of Respiratory and Critical Care Medicine concluded that the T-SPOT.TB test is better than the tuberculin skin test at predicting which patients will develop active TB.

20 Jul 2010

Mayo Clinic's July issue offers tips on ophthalmology, Alzheimer's and CKD

Here are highlights from the July issue of Mayo Clinic Women's HealthSource. You may cite this publication as often as you wish. Mayo Clinic Women's HealthSource attribution is required.

20 Jul 2010

Lots of water breaks prevent dehydration in kids

Scorching heat has taken its toll across the country this summer with record temperatures and heat indexes reaching well above 100 degrees. Add kids playing outside and outdoor summer activities in full swing to the dangerous heat you've got a hazardous combination.

20 Jul 2010

DEKA Medical announces availability of new SmartXide DOT HP Fractional CO2 laser

DEKA Medical announced today the immediate availability of the High-Powered SmartXide DOT. The new SmartXide DOT HP Fractional CO2 laser, with average power of 50W, can attain irradiance of up to 250W of power with each pulse. This makes the new SmartXide DOT HP the most powerful superpulse CO2 laser available to aesthetic physicians.

19 Jul 2010

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine-based immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data on the Company's novel DermaVir therapeutic vaccine for HIV/AIDS during the XVIII International AIDS Conference this week in Vienna, Austria. DermaVir, the first dendritic cell-targeting topical HIV vaccine candidate, employs nanotechnology to induce multi-faceted and long-lived immune responses capable of eliminating HIV infected cells.

19 Jul 2010

Study evaluates immunization benefits of dissolving microneedles

A new vaccine-delivery patch based on hundreds of microscopic needles that dissolve into the skin could allow persons without medical training to painlessly administer vaccines - while providing improved immunization against diseases such as influenza.

19 Jul 2010

Tet 1 protein helps stem cells renew themselves and stay pluripotent: Researchers

Take a skin cell from a patient with Type 1 diabetes. Strip out everything that made it a skin cell, then reprogram it to grow into a colony of pancreatic beta cells. Implant these into your patient and voilà! She's producing her own insulin like a pro.

19 Jul 2010

CCTP focuses on identifying, testing drugs for cancer stem cell treatment

Cancer and stem cell biology researchers at the University of Colorado are launching the nation's first program focused on identifying and testing drugs that target and destroy cells thought to be at the root of cancer-cancer stem cells (CSCs).The Cancer Stem Cell-Directed Clinical Trials Program (CCTP) is a collaboration between the University of Colorado Cancer Center and the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, both located at the University of Colorado School of Medicine.

17 Jul 2010

Research findings may help identify human TOR kinase inhibitors

A parasite estimated to afflict as many as 12 million people worldwide relies on a family of genes that should make it vulnerable to compounds developed to treat cancer and other disorders, researchers at Washington University School of Medicine in St. Louis have found.

17 Jul 2010

Survival rates of nine types of cancer in Spain

Spanish epidemiologists have presented information on survival of nine types of cancer in Spain and have compared it with other European countries. At five years from diagnosis, the lowest survival rate is observed in lung cancer (less than 11%), and the highest in testicular cancer (95%). Cancer survival in Spain is at the European average.

16 Jul 2010